灵康药业: 2025年半年度业绩预告

Group 1 - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between -39.5 million and -35 million yuan, with a net profit excluding non-recurring gains and losses estimated between -48.5 million and -44 million yuan [1][2] - The projected operating revenue for the first half of 2025 is estimated to be between 160 million and 200 million yuan, with the revenue from core business activities expected to be between 153.4 million and 160 million yuan [1][2] - The company reported a net profit attributable to shareholders of the parent company for the same period last year of -40.4 million yuan, with a net profit excluding non-recurring gains and losses of -54.4 million yuan [2] Group 2 - The primary reason for the expected loss is that the gross profit from sales is insufficient to cover the period expenses, leading to a loss for the current period [2] - The company has increased efforts in promoting products that have won centralized procurement bids and is leveraging its channel advantages to enhance market promotion of non-procurement products [2] - The company aims to expand its pharmaceutical distribution business to strengthen its overall scale [2]